Risk factor
Meaningful price volatility
Profitability factor
Solid dividends
About
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is of fair value on EV/EBITDA, un
Target Price
The average target price of 137310.KS is 9000 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat
